Lancet Oncol 2024; 25: 1176-87 更正

The Lancet Oncology Pub Date : 2024-10-25 DOI:10.1016/s1470-2045(24)00626-0

{"title":"Lancet Oncol 2024; 25: 1176-87 更正","authors":"","doi":"10.1016/s1470-2045(24)00626-0","DOIUrl":null,"url":null,"abstract":"Vera P, Thureau S, Le Tinier F, et al. Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial. Lancet Oncol 2024; 25: 1176–87—In this Article, Pierre Boissellier should have been spelled Pierre Boisselier. This correction has been made to the online version as of Oct 25, 2024.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"96 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to Lancet Oncol 2024; 25: 1176–87\",\"authors\":\"\",\"doi\":\"10.1016/s1470-2045(24)00626-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Vera P, Thureau S, Le Tinier F, et al. Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial. Lancet Oncol 2024; 25: 1176–87—In this Article, Pierre Boissellier should have been spelled Pierre Boisselier. This correction has been made to the online version as of Oct 25, 2024.\",\"PeriodicalId\":22865,\"journal\":{\"name\":\"The Lancet Oncology\",\"volume\":\"96 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s1470-2045(24)00626-0\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s1470-2045(24)00626-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

Vera P, Thureau S, Le Tinier F, et al. 根据42 Gy时[18F]FDG-PET肿瘤残留摄取量对III期非小细胞肺癌患者进行适应性放疗（最高74 Gy）或标准放疗（66 Gy）（RTEP7-IFCT-1402）：一项多中心随机对照2期试验。Lancet Oncol 2024; 25: 1176-87-在本文中，Pierre Boissellier应拼写为Pierre Boisselier。在线版本已于2024年10月25日进行了更正。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Correction to Lancet Oncol 2024; 25: 1176–87

Vera P, Thureau S, Le Tinier F, et al. Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial. Lancet Oncol 2024; 25: 1176–87—In this Article, Pierre Boissellier should have been spelled Pierre Boisselier. This correction has been made to the online version as of Oct 25, 2024.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Lancet Oncology

自引率

0.00%

发文量